These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 33863352

  • 1. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
    Combe B, Allanore Y, Alten R, Caporali R, Durez P, Iannone F, Nurmohamed MT, Toumi M, Lee SJ, Kwon TS, Noh J, Park G, Yoo DH.
    Arthritis Res Ther; 2021 Apr 16; 23(1):119. PubMed ID: 33863352
    [Abstract] [Full Text] [Related]

  • 2. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, Abud-Mendoza C, Navarra S, Kadinov V, Sariego IG, Hong SS, Lee SY, Park W.
    Arthritis Res Ther; 2016 Apr 02; 18():82. PubMed ID: 27038608
    [Abstract] [Full Text] [Related]

  • 3. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
    Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Müller-Ladner U.
    Ann Rheum Dis; 2013 Oct 02; 72(10):1613-20. PubMed ID: 23687260
    [Abstract] [Full Text] [Related]

  • 4. Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.
    Kim HA, Lee E, Lee SK, Park YB, Lee YN, Kang HJ, Shin K.
    BioDrugs; 2020 Feb 02; 34(1):89-98. PubMed ID: 31734899
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R, Allanore Y, Alten R, Combe B, Durez P, Iannone F, Nurmohamed MT, Lee SJ, Kwon TS, Choi JS, Park G, Yoo DH.
    Expert Rev Clin Immunol; 2021 Jan 02; 17(1):85-99. PubMed ID: 33305638
    [Abstract] [Full Text] [Related]

  • 6. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME, Hsia E, Aletaha D.
    Arthritis Rheumatol; 2017 Mar 02; 69(3):518-528. PubMed ID: 27696724
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W.
    Ann Rheum Dis; 2017 Feb 02; 76(2):355-363. PubMed ID: 27130908
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.
    Constantin A, Caporali R, Edwards CJ, Fonseca JE, Iannone F, Keystone E, Schulze-Koops H, Kwon T, Kim S, Yoon S, Kim DH, Park G, Yoo DH.
    Rheumatology (Oxford); 2023 Aug 01; 62(8):2838-2844. PubMed ID: 36534825
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S.
    J Crohns Colitis; 2022 Sep 08; 16(9):1436-1446. PubMed ID: 35390141
    [Abstract] [Full Text] [Related]

  • 11. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS.
    Semin Arthritis Rheum; 2020 Apr 08; 50(2):276-284. PubMed ID: 31590930
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT, Brook J, Ben-Artzi A, Martin W, Kermani TA, Avedikian-Tatosyan L, Karpouzas G, Nagam H, Navarro G, Choi S, Taylor MB, Elashoff D, Kaeley GS, Ranganath VK.
    Clin Rheumatol; 2021 Dec 08; 40(12):5055-5065. PubMed ID: 34269927
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L.
    Arthritis Res Ther; 2018 Jan 16; 20(1):8. PubMed ID: 29338762
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
    D'Agostino MA, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G.
    Clin Rheumatol; 2017 Dec 16; 36(12):2655-2665. PubMed ID: 28822046
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
    Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, Balázs É, Shevchuk S, Eliseeva L, Stanislavchuk M, Yatsyshyn R, Hrycaj P, Jaworski J, Zhdan V, Trefler J, Shesternya P, Lee SJ, Kim SH, Suh JH, Lee SG, Han NR, Yoo DH.
    Rheumatology (Oxford); 2021 May 14; 60(5):2277-2287. PubMed ID: 33230526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.